Clinical Trial Update: Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma) [Phase 1]

View source ↗

Summary

This document reports a completed Phase 1 study evaluating the combination of GC33 and sorafenib for advanced or metastatic hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• GC33 (codrituzumab)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Chugai Pharmaceutical | Conditions: Hepatocellular Carcinoma | Phase 1 | Status: COMPLETED